MENU

NEWSROOM

Title

  1. First PRRT clinical trial launched in Shanghai
  2. More accurate prediction of recurrence risk! The FUSCC team provides new "weapon" for postoperative management of colorectal cancer patients
  3. FUSCC-NMRRC joint webinar on “The treatment of oligo metastatic prostate cancer”
  4. Fudan University Shanghai Cancer Center revealed a unique T cell subset in the immune microenvironment of HPV-positive oropharyngeal carcinoma
  5. The study “clinical value of 68Ga-FAPI PET/CT in platinum-sensitive recurrent ovarian cancer” performed by Nuclear Medicine Department of Shanghai Cancer Center has been recognized internationally
  6. Prof. Zhiguo Luo and his team published the result of a phase II study of soft tissue sarcoma on Clinical Cancer Research
  7. FUSCC research team reveals characteristics of gut microbiome, metabolites, microbial enzyme genes in EO-CRC
  8. Chinese prostate cancer drug shows promising results
  9. Simultaneous cervicothoracic thymic cancer and thyroid cancer removed in a single operation
  10. The researches from Fudan University Shanghai Cancer Center mapped the proteogenomic profile of clear cell renal cell carcinoma